Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine + cyclopropofol vs sufentanil + cyclopropofol for painless gastrointestinal endoscopy
ChiCTR2400090063Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gastrointestinal conditions comparing Nalbuphine + cyclopropofol with Sufentanil + cyclopropofol (2 arms). Primary endpoints: Discomfort score, Depth of sedation and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
nalbuphineciprofolsufentanil
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on ChiCTR2400090063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090063.